These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2274627)

  • 1. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination.
    Simeon JG; Thatte S; Wiggins D
    Psychopharmacol Bull; 1990; 26(3):285-90. PubMed ID: 2274627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B; Bonnet-Perrin E
    Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
    Hantouche EG; Bouhassira M; Lancrenon S
    Encephale; 2000; 26(6):73-83. PubMed ID: 11217541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder.
    Wald R; Dodman N; Shuster L
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):191-7. PubMed ID: 19586234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
    Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
    J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obsessive-compulsive-bipolar comorbidity: a systematic exploration of clinical features and treatment outcome.
    Perugi G; Toni C; Frare F; Travierso MC; Hantouche E; Akiskal HS
    J Clin Psychiatry; 2002 Dec; 63(12):1129-34. PubMed ID: 12523872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(4):677-82. PubMed ID: 8993091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder.
    Diniz JB; Costa DL; Cassab RC; Pereira CA; Miguel EC; Shavitt RG
    J Psychopharmacol; 2014 Jun; 28(6):603-11. PubMed ID: 24288238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment.
    Kawahara T; Ueda Y; Mitsuyama Y
    Psychiatry Clin Neurosci; 2000 Oct; 54(5):599-601. PubMed ID: 11043813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous anti-obsessive agents: a review.
    Ravindran LN; Jung SM; Ravindran AV
    J Psychopharmacol; 2010 Mar; 24(3):287-96. PubMed ID: 18801828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clomipramine-resistant, fluoxetine-responsive obsessive compulsive disorder: a case report.
    Paholpak S
    J Med Assoc Thai; 2002 Oct; 85(10):1135-8. PubMed ID: 12501907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side effects as predictors of drug response in obsessive-compulsive disorder.
    Ackerman DL; Greenland S; Bystritsky A
    J Clin Psychopharmacol; 1999 Oct; 19(5):459-65. PubMed ID: 10505588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citalopram for treatment-resistant obsessive-compulsive disorder.
    Pallanti S; Quercioli L; Paiva RS; Koran LM
    Eur Psychiatry; 1999 Apr; 14(2):101-6. PubMed ID: 10572334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritanserin as adjunct to fluoxetine treatment of OCD patients with psychotic features.
    Bach M; Aigner M; Lenz G
    Pharmacopsychiatry; 1997 Jan; 30(1):28-9. PubMed ID: 9065968
    [No Abstract]   [Full Text] [Related]  

  • 16. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
    Todorov C; Freeston MH; Borgeat F
    Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amantadine augmentation for refractory obsessive-compulsive disorder: a case report.
    Pasquini M; Berardelli I; Biondi M
    J Clin Psychopharmacol; 2010 Feb; 30(1):85-6. PubMed ID: 20075660
    [No Abstract]   [Full Text] [Related]  

  • 18. Elevated thyroid indices in children and adolescents with obsessive-compulsive disorder: effects of clomipramine treatment.
    McCracken JT; Hanna GL
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):581-7. PubMed ID: 16190790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder.
    Go FS; Malley EE; Birmaher B; Rosenberg DR
    J Child Adolesc Psychopharmacol; 1998; 8(1):73-80. PubMed ID: 9639082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents.
    Figueroa Y; Rosenberg DR; Birmaher B; Keshavan MS
    J Child Adolesc Psychopharmacol; 1998; 8(1):61-7. PubMed ID: 9639080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.